The combination of 2% 4-hydroxyanisole (mequinol) and 0.01% tretinoin effectively improves the appearance of solar lentigines in ethnic groups

Journal of Cosmetic Dermatology

Volumn 5, Issue 3, 2006, Pages 239-244

  Draelos, Zoe Diana ^a  

^a NONE   (United States)

Author keywords

Ethnic groups; Mequinol; Solar lentigines; Tretinoin

Indexed keywords

MEQUINOL PLUS RETINOIC ACID;

ACCIDENTAL INJURY; ADULT; AFRICAN AMERICAN; AGED; ARTICLE; ASIAN; CLINICAL TRIAL; DESQUAMATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRY SKIN; ERYTHEMA; ETHNOLOGY; FEMALE; FLU LIKE SYNDROME; HEMATURIA; HISPANIC; HUMAN; HYPOPIGMENTATION; IRRITANT DERMATITIS; LABORATORY TEST; LENTIGINOSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN STUDY; PHARYNGITIS; PRIORITY JOURNAL; PRURITUS; RESPIRATORY TRACT DISEASE; RISK BENEFIT ANALYSIS; SCORING SYSTEM; SKIN DISCOMFORT; SKIN PIGMENTATION; TREATMENT OUTCOME; UROGENITAL TRACT DISEASE;

ADULT; AGED; AGED, 80 AND OVER; ANISOLES; ANTIOXIDANTS; DRUG COMBINATIONS; ETHNIC GROUPS; FACE; FEMALE; HUMANS; KERATOLYTIC AGENTS; LENTIGO; MALE; MIDDLE AGED; TRETINOIN;

EID: 33748194277     PISSN: 14732130     EISSN: 14732165     Source Type: Journal    
DOI: 10.1111/j.1473-2165.2006.00260.x     Document Type: Article

References (28)

1. Farris PK. Combination therapy for solar lentigines. J Drugs Dermatol 2004; 3: S23-S26.
2. Fleisher AB, Schwartzel EH, Colby SI et al. The combination of 2% 4-hydroxyanisole (mequinol) and 0.01% tretinoin is effective in improving the appearance of solar lentigines and related hyperpigmented lesions in two double-blind multicenter clinical studies. J Am Acad Dermatol 2000; 42: 459-67.
3. Ortonne JP, Camacho F, Wainwright N, Bergfelt L, Westerhof W, Roseeuw D. Safety and efficacy of combined use of 4-hyroxyanisole (mequinol) 2%;/ tretinoin 0.01% solution and sunscreen in solar lentigines. Cutis 2004; 74: 261-4.
4. 1996 US Government Census Report, Washington, DC: Government Printing Office; 1996.
5. Hermanns JF, Petit L, Piérard-Franchimont C, Paquet P, Piérard GE. Assessment of topical hypopigmenting agents on solar lentigines of Asian women. Dermatology 2002; 204: 281-6.
6. Petit L, Piérard GE. Analytic quantification of solar lentigines lightening by a 2% hydroquinone-cyclodextrin formulation. J Eur Acad Dermatol Venereol 2003; 17: 546-9.
7. Yoshimura K, Harii K, Aoyama T, Iga T. Experience with a strong bleaching treatment for skin hyperpigmentation in Orientals. Plast Reconstr Surg 2000; 105: 1097-110.
8. Colby SI, Schwartzel EH, Huber FJ et al. A promising new treatment for solar lentigines. J Drugs Dermatol 2003; 2: 147-52.
9. Jarrat M. Mequinol 2%/tretinoin 0.01% solution: An effective and safe alternative to hydroquinone 3% in the treatment of solar lentigines. Cutis 2004; 74: 319-22.
10. Akdeniz N, Calka O, Ozbek H, Metin A. Anti-inflammatory effects of tretinoin (all-trans-retinoic acid) 0.1% and adapalene 0.1% in rats. Clin Exp Dermatol 2005; 30: 570-2.
11. Bessou S, Pain C, Taieb A. Use of human skin reconstructs in the study of pigment modifiers. Arch Dermatol 1997; 133: 331-6.
12. Belcher HJ, Nizam M, O'Neill TJ. Intra-arterial 4-hydroxyanisole chemotherapy for locally recurrent malignant melanoma: A re-appraisal. Br J Plastic Surg 1992; 45: 208-10.
13. Garcia Reverte JM, Bernabeu Esclapez A, Munoz Ramos J, Vicente Ortega V, Canteras Jordana M. Effects of various antineoplastic agents on an established human melanoma cell line (G-361). Histol Histopathol 1995; 10: 79-84.
14. Koga S, Nakano M, Ito T, Tomita Y. Importance of iron in lipid peroxidation in the tyrosinase/4-hydroxyanisole system: Possible mechanism of killing of malignant melanoma cells by 4-hydroxyanisole. Biochem Int 1992; 26: 397-403.
15. Katsambas A, Antoniou C. Melasma. Classification and treatment. J Eur Acad Dermatol Venereol 1995; 4: 217-23.
16. Food and Drug Administration. (2005) Tri-Luma™ Cream. [WWW document]. URL http://www.fda.gov/cder/foi/label/2002/21112lbl.pdf (Accessed 2 September 2005).
17. Grimes PE. A microsponge formulation of hydroquinone 4% and retinol 0.15% in the treatment of melasma and postinflammatory hyperpigmentation. Cutis 2004; 74: 362-8.
18. Szabo G. Pigment cell biology. In: M Gordon, ed. Mitochondria and Other Cytoplasmic Inclusions. New York: Academic Press; 1959.
19. Staricco RS, Pinkus H. Quantitative and qualitative data on the pigment cells of adult human epidermis. J Invest Dermatol 1957; 28: 33-45.
20. Toda K, Patnak MA, Parrish A, Fitzpatrick TB, Quevedo WC. Alteration of racial differences in melanosome distribution in human epidermis after exposure to ultraviolet light. Nat New Biol 1972; 236: 143-4.
21. Reed JT, Ghadially R, Elias PM. Skin type, but neither race nor gender, influence epidermal permeability barrier function. Arch Dermatol 1995; 131: 1134-8.
22. Wedig JH, Maibach HI. Percutaneous penetration of dipyrithione in men: effect of skin color (race). J Am Acad Dermatol 1981; 5: 433-8.
23. Berardesca E, Maibach HI. Racial differences in sodium lauryl sulfate induced cutaneous irritation: Black and white. Contact Dermatitis 1988; 18: 65-70.
24. Berardesca E, Maibach HI. Sodium-lauryl-sulphate-induced cutaneous irritation comparison of white and Hispanic subjects. Contact Dermatitis 1988; 19: 136-40.
25. Berardesca E. Racial differences in skin function. Acta Derm Venereol 1994; 185 (Suppl.): 44-6.
26. Wilson D, Berardesca E, Maibach HI. In vitro transepidermal water loss: differences between black and white human skin. Br J Dermatol 1988; 119: 647-52.
27. Berardesca E, Maibach HI. Sensitive and ethnic skin: A need for special skin care agent? Dermatol Clin 1991; 9: 89-92.
28. Bongiorno MR, Arico M. Exogenous ochronosis and striae atrophicae following the use of bleaching creams. Int J Dermatol 2005; 44: 112-5.